Federal Register / Vol. 75, No. 212 / Wednesday, November 3, 2010 / Notices 67749 

noted, nonbanking activities will be 

conducted throughout the United States. 

Unless otherwise noted, comments 

regarding each of these applications 

must be received at the Reserve Bank 

indicated or the offices of the Board of 

Governors not later than November 26, 

2010. 

A. Federal Reserve Bank of Chicago 

(Colette A. Fried, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414: 

1. Peoples Bancorp, Inc., Prairie du 

Chien, Wisconsin; to acquire 100 

percent of the voting shares of 

Woodhouse & Bartley Bank, 

Bloomington, Wisconsin. 

B. Federal Reserve Bank of Kansas 

City (Dennis Denney, Assistant Vice 

President) 1 Memorial Drive, Kansas 

City, Missouri 64198–0001: 

1. Exchange Bancorp of Missouri, Inc., 

Fayette, Missouri; to become a bank 

holding company by acquiring 100 

percent of the voting shares of Exchange 

Bank of Missouri, Fayette, Missouri. 

Board of Governors of the Federal Reserve 

System, October 28, 2010. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. 2010–27684 Filed 11–2–10; 8:45 am] 

BILLING CODE 6210–01–P 

FEDERAL MARITIME COMMISSION 

Notice of Agreements Filed 

The Commission hereby gives notice 

of the filing of the following agreements 

under the Shipping Act of 1984. 

Interested parties may submit comments 

on the agreements to the Secretary, 

Federal Maritime Commission, 

Washington, DC 20573, within ten days 

of the date this notice appears in the 

Federal Register. Copies of the 

agreements are available through the 

Commission’s Web site (http:// 

www.fmc.gov) or by contacting the 

Office of Agreements at (202) 523–5793 

or tradeanalysis@fmc.gov. 

Agreement No.: 001941–003. 

Title: Baltimore Marine Terminal 

Association. 

Parties: Ports Baltimore, Inc.; 

Maryland International Terminals, Inc.; 

Mid-Atlantic Terminal LLC; Ceres 

Marine terminals, Inc.; Tartan 

Terminals, Inc. and Ports America 

Chesapeake, Inc. 

Filing Party: JoAnne Zawitoski, Esq.; 

Baltimore Marine Terminal Association; 

25 South Charles Street, Suite 1400, 

Baltimore, MD 21201. 

Synopsis: The amendment restates the 

agreement and identifies the current 

members of the BTMA. 

Agreement No.: 011435–014. 

Title: APL/HLAG Space Charter 

Agreement. 

Parties: American President Lines, 

Ltd.; APL Co. Pte Ltd.; and Hapag-Lloyd 

AG. 

Filing Party: Wayne R. Rohde, Esq.; 

Cozen O’Connor; 1627 I Street, NW., 

Suite 1100, Washington, DC 20006. 

Synopsis: The amendment updates 

the corporate address for APL. 

Agreement No.: 011741–015. 

Title: U.S. Pacific Coast-Oceania 

Agreement. 

Parties: ANL Singapore PTE Ltd.; A.P. 

Moller-Maersk A/S; CMA CGM S.A.; 

Hamburg-Su ̈d; and Hapag-Lloyd AG. 

Filing Party: Wayne R. Rohde, Esq.; 

Cozen O’Connor; 1627 I Street, NW., 

Suite 1100, Washington, DC 20006. 

Synopsis: The amendment increases 

the amount of space CMA CGM is 

allotted from Pacific Northwest ports. 

Agreement No.: 012077–001. 

Title: APL/Maersk Line Reciprocal 

Space Charter Agreement. 

Parties: American President Lines, 

Ltd.; APL Co. Pte, Ltd.; and A.P. Moller 

Maersk A/S. 

Filing Party: Eric. C. Jeffrey, Esq.; 

Counsel for APL; Goodwin Procter LLP; 

901 New York Avenue, NW., 

Washington, DC 20001. 

Synopsis: The amendment updates 

the corporate addresses of American 

President Lines, Ltd. and APL Co. Pte 

Ltd. 

Agreement No.: 012108. 

Title: The World Liner Data 

Agreement. 

Parties: A.P. Moller-Maersk A/S; CMA 

CGM S.A.; Compania Chilena de 

Navegacion Interoceanica S.A.; 

Hamburg-Sud; Hapag-Lloyd AG; Orient 

Overseas Container Line Ltd.; and 

United Arab Shipping Company S.A.G. 

Filing Party: Wayne Rohde, Esq.; 

Cozen O’Connor; 627 I Street, NW., 

Suite 1100, Washington, DC 20006. 

Synopsis: The pending agreement has 

been changed to include CCNI and 

Orient Overseas Container Line Ltd as 

parties to the Agreement. 

Agreement No.: 201209. 

Title: Marine Terminal Lease and 

Operating Agreement Between Broward 

County and Seafreight Agencies (USA), 

Inc. 

Parties: Broward County and 

Seafreight Agencies (USA), Inc. 

Filing Party: Candace J. Running; 

Broward County Board of County 

Commissioners; Office of the County 

Attorney; 1850 Eller Drive, Suite 502, 

Fort Lauderdale, FL 33316. 

Synopsis: The agreement provides for 

the lease and operation of terminal 

facilities at Port Everglades in Broward 

County, Florida. 

By Order of the Federal Maritime 

Commission. 

Dated: October 29, 2010. 

Karen V. Gregory, 

Secretary. 

[FR Doc. 2010–27777 Filed 11–2–10; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories and 

Instrumented Initial Testing Facilities 

Which Meet Minimum Standards To 

Engage in Urine Drug Testing for 

Federal Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908); 

September 30, 1997 (62 FR 51118); 

April 13, 2004 (69 FR 19644); November 

25, 2008 (73 FR 71858); December 10, 

2008 (73 FR 75122); and on April 30, 

2010 (75 FR 22809). 

A notice listing all currently certified 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) is published in 

the Federal Register during the first 

week of each month. If any Laboratory/ 

IITF’s certification is suspended or 

revoked, the Laboratory/IITF will be 

omitted from subsequent lists until such 

time as it is restored to full certification 

under the Mandatory Guidelines. 

If any Laboratory/IITF has withdrawn 

from the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http://www.workplace.

samhsa.gov and http://www.

drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 2– 

1042, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 


jlentini on DSKJ8SOYB1PROD with NOTICES
67750 Federal Register / Vol. 75, No. 212 / Wednesday, November 3, 2010 / Notices 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were initially 

developed in accordance with Executive 

Order 12564 and section 503 of Public 

Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs,’’ as amended in the 

revisions listed above, requires {or set} 

strict standards that Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) must meet in order to conduct 

drug and specimen validity tests on 

urine specimens for Federal agencies. 

To become certified, an applicant 

Laboratory/IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a Laboratory/IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) in the applicant 

stage of certification are not to be 

considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A Laboratory/ 

IITF must have its letter of certification 

from HHS/SAMHSA (formerly: HHS/ 

NIDA) which attests that it has met 

minimum standards. 

In accordance with the Mandatory 

Guidelines dated November 25, 2008 

(73 FR 71858), the following 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Instrumented Initial Testing Facilities 

(IITF): 

None. 

Laboratories: 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227, 414–328– 

7840/800–877–7016 (Formerly: 

Bayshore Clinical Laboratory). 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

585–429–2264. 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118, 901–794–5770/888–290– 

1150. 

Aegis Analytical Laboratories, 345 

Hill Ave., Nashville, TN 37210, 615– 

255–2400 (Formerly: Aegis Sciences 

Corporation, Aegis Analytical 

Laboratories, Inc.). 

Alere Toxicology Services, 1111 

Newton St., Gretna, LA 70053, 504– 

361–8989/800–433–3823 (Formerly: 

Kroll Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.). 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 23236, 

804–378–9130 (Formerly: Kroll 

Laboratory Specialists, Inc., Scientific 

Testing Laboratories, Inc.; Kroll 

Scientific Testing Laboratories, Inc.). 

Baptist Medical Center-Toxicology 

Laboratory, 11401 I–30, Little Rock, AR 

72209–7056, 501–202–2783 (Formerly: 

Forensic Toxicology Laboratory Baptist 

Medical Center). 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802, 800– 

445–6917. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602, 229–671– 

2281. 

DrugScan, Inc. P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974, 

215–674–9310. 

DynaLIFE Dx *, 10150–102 St., Suite 

200, Edmonton, Alberta, Canada T5J 

5E2, 780–451–3702/800–661–9876 

(Formerly: Dynacare Kasper Medical 

Laboratories). 

ElSohly Laboratories, Inc., 5 

Industrial Park Drive, Oxford, MS 

38655, 662–236–2609. 

Gamma-Dynacare Medical 

Laboratories*, A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630. 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986 

(Formerly: Roche Biomedical 

Laboratories, Inc.). 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709, 919– 

572–6900/800–833–3984 (Formerly: 

LabCorp Occupational Testing Services, 

Inc., CompuChem Laboratories, Inc.; 

CompuChem Laboratories, Inc., A 

Subsidiary of Roche Biomedical 

Laboratory; Roche CompuChem 

Laboratories, Inc., A Member of the 

Roche Group). 

Laboratory Corporation of America 

Holdings, 1120 Main Street, Southaven, 

MS 38671, 866–827–8042/800–233– 

6339 (Formerly: LabCorp Occupational 

Testing Services, Inc.; MedExpress/ 

National Laboratory Center). 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 66219, 

913–888–3927/800–873–8845 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.,). 

Maxxam Analytics*, 6740 

Campobello Road, Mississauga, ON, 

Canada L5N 2L8, 905–817–5700 

(Formerly: Maxxam Analytics Inc., 

NOVAMANN (Ontario), Inc.). 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244. 

MetroLab-Legacy Laboratory Services, 

1225 NE 2nd Ave., Portland, OR 97232, 

503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology Laboratory, 

1 Veterans Drive, Minneapolis, MN 

55417, 612–725–2088. 

National Toxicology Laboratories, 

Inc., 1100 California Ave., Bakersfield, 

CA 93304, 661–322–4250/800–350– 

3515. 

One Source Toxicology Laboratory, 

Inc., 1213 Genoa-Red Bluff, Pasadena, 

TX 77504, 888–747–3774 (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory). 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942 (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory). 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204, 509–755–8991/ 

800–541–7891x7. 

Phamatech, Inc., 10151 Barnes 

Canyon Road, San Diego, CA 92121, 

858–643–5555. 

Quest Diagnostics Incorporated, 1777 

Montreal Circle, Tucker, GA 30084, 

800–729–6432 (Formerly: SmithKline 

Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories). 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories). 

Quest Diagnostics Incorporated, 8401 

Fallbrook Ave., West Hills, CA 91304, 

800–877–2520 (Formerly: SmithKline 

Beecham Clinical Laboratories). 

S.E.D. Medical Laboratories, 5601 

Office Blvd., Albuquerque, NM 87109, 

505–727–6300/800–999–5227. 

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, IN 

46601, 574–234–4176 x1276. 

Southwest Laboratories, 4625 E. 

Cotton Center Boulevard, Suite 177, 

Phoenix, AZ 85040, 602–438–8507/800– 

279–0027. 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., Oklahoma 

City, OK 73101, 405–272–7052. 

Sterling Reference Laboratories, 2617 

East L Street, Tacoma, Washington 

98421, 800–442–0438. 

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 

70 West, Suite 208, Columbia, MO 

65203, 573–882–1273. 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 212 / Wednesday, November 3, 2010 / Notices 67751 

Toxicology Testing Service, Inc., 5426 

N.W. 79th Ave., Miami, FL 33166, 305– 

593–2260. 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755–5235, 

301–677–7085. 

*The Standards Council of Canada 

(SCC) voted to end its Laboratory 

Accreditation Program for Substance 

Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that 

program were accredited to conduct 

forensic urine drug testing as required 

by U.S. Department of Transportation 

(DOT) regulations. As of that date, the 

certification of those accredited 

Canadian laboratories will continue 

under DOT authority. The responsibility 

for conducting quarterly performance 

testing plus periodic on-site inspections 

of those LAPSA-accredited laboratories 

was transferred to the U.S. HHS, with 

the HHS’ NLCP contractor continuing to 

have an active role in the performance 

testing and laboratory inspection 

processes. Other Canadian laboratories 

wishing to be considered for the NLCP 

may apply directly to the NLCP 

contractor just as U.S. laboratories do. 

Upon finding a Canadian laboratory to 

be qualified, HHS will recommend that 

DOT certify the laboratory (Federal 

Register, July 16, 1996) as meeting the 

minimum standards of the Mandatory 

Guidelines published in the Federal 

Register on April 30, 2010 (75 FR 

22809). After receiving DOT 

certification, the laboratory will be 

included in the monthly list of HHScertified laboratories and participate in 

the NLCP certification maintenance 

program. 

Dated: October 28, 2010. 

Elaine Parry, 

Director, Office of Management, Technology, 

and Operations, SAMHSA. 

[FR Doc. 2010–27728 Filed 11–2–10; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–5055–N] 

Medicare Program: Community-Based 

Care Transitions Program (CCTP) 

Meeting 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice of meeting. 

SUMMARY: This notice announces a 

public conference hosted by CMS. This 

conference will provide a forum for 

community-based organizations, 

hospitals, Quality Improvement 

Organizations, Administration on Aging 

grantees, and other healthcare providers 

to receive useful guidance and ask 

questions about the upcoming 

Community-based Care Transitions 

Program. The meeting is open to the 

public, but attendance is limited to 

space and Webinar lines available. 

DATES: Meeting Date: Friday, December 

3, 2010, from 8 a.m. to 4 p.m., eastern 

standard time (e.s.t.). 

Deadline for Webinar or Web-based 

Registration: Thursday, December 2, 

2010, 8 a.m., e.s.t. 

Deadline for Meeting Registration: 

Friday, November 19, 2010, 4 p.m., e.s.t. 

Limited walk-in registration may be 

available the evening prior to the 

conference and the morning of the 

conference as space permits. 

ADDRESSES: Meeting Location: Marriott 

Waterfront Hotel, 700 Aliceanna Street, 

Baltimore, MD 21202. 

Registration: The meeting is open to 

the public, but attendance is limited to 

space and Webinar lines available. A 

link to the agenda and registration 

information will be posted on the CMS 

Care Transitions Web site at http:// 

www.cms.gov/DemoProjectsEvalRpts/ 

MD/ 

itemdetail.asp?itemID=CMS1239313 as 

soon as it is available. Persons wishing 

to attend this meeting in person or via 

Webinar are encouraged to register in 

advance. 

Special Accommodations: Individuals 

who require special accommodations 

should send an e-mail request to 

CareTransitions@cms.hhs.gov or via 

regular mail to the address specified in 

the FOR FURTHER INFORMATION CONTACT

section of this notice. Presentation 

materials will be posted on the CMS 

Care Transitions Web site prior to the 

meeting. 

FOR FURTHER INFORMATION CONTACT: 

Juliana Tiongson, Social Science 

Research Analyst, Centers for Medicare 

& Medicaid Services, 7500 Security 

Boulevard, Baltimore, MD 21244–1850, 

Mail Stop C4–14–15, telephone 410– 

786–0342 or e-mail 

Juliana.Tiongson@cms.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

Community-based organizations 

(CBOs) are defined in the statute as 

community-based organizations that 

provide care transition services across a 

continuum of care through 

arrangements with subsection (d) 

hospitals (as defined in section 

1886(d)(1)(B) of the Social Security Act) 

and whose governing body includes 

sufficient representation of multiple 

health care stakeholders, including 

consumers. Experts in the field will 

present evidence-based care transition 

models, and lessons learned from 

participation in the Quality 

Improvement Organizations’ (QIOs) 9th 

scope of work care transitions subnational theme and related initiatives. 

Healthcare leaders will present broader, 

hospital-based interventions to reduce 

readmissions, as well as the positive 

financial implications of successfully 

reducing readmissions. This conference 

will also provide an overview of the 

Community-based Care Transitions 

Program (CCTP) and provide the 

opportunity for hospitals to connect 

with CBOs in their communities. Once 

a solicitation for the CCTP is published, 

proposals will be accepted on a rolling 

quarterly basis beginning in early 2011. 

II. Meeting Agenda 

The agenda for the December 3, 2010 

meeting will include the following topic 

areas: 

• Overview of the CCTP under 

section 3026 of the Affordable Care Act. 

• The Business Case for Improving 

Care Transitions. 

• Building Community Support and 

Root Cause Analysis. 

• Overview of Care Transition 

Interventions. 

• Implementation of Care Transition 

Interventions—Successes and 

Challenges. 

Authority: Section 3026 of the Affordable 

Care Act 

Dated: October 21, 2010. 

Donald M. Berwick, 

Administrator, Centers for Medicare & 

Medicaid Services. 

[FR Doc. 2010–27789 Filed 10–29–10; 4:15 pm] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, 

November 18, 2010, 2 p.m. to November 

18, 2010, 4 p.m., National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, 

MD 20892 which was published in the 

Federal Register on October 25, 2010, 

75 FR 65498–65499. 

The meeting title has been changed to 

‘‘RFA Panel: Translational Research in 

Pediatric and Obstetric Pharmacology’’. 

The meeting is closed to the public. 


jlentini on DSKJ8SOYB1PROD with NOTICES